An experimental drug for prevention of chronic migraine headaches from Amgen Inc met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo, the company said on Wednesday.
The biotech drug, erenumab, which is being co-developed with Swiss drugmaker Novartis, was tested at two doses in a 12-week, 667-patient Phase II study of subjects who were experiencing about 18 migraine days a month.
Source: Reuters
Filed Under: Drug Discovery